Survival in familial idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis.

Deborah Reis Estrella, Eliane Mancuzo, Ricardo De Amorim Correa, Regina Tibana, Maria Raquel Soares, Carlos Alberto De Castro Pereira
{"title":"Survival in familial idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis.","authors":"Deborah Reis Estrella, Eliane Mancuzo, Ricardo De Amorim Correa, Regina Tibana, Maria Raquel Soares, Carlos Alberto De Castro Pereira","doi":"10.36141/svdld.v42i4.16938","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Familial pulmonary fibrosis (FPF) is defined as the occurrence of any interstitial lung disease (ILD) in two or more first- or second-degree relatives. Although the most frequently reported phenotype is idiopathic pulmonary fibrosis (IPF), other forms of ILD have been identified, such as fibrotic hypersensitivity pneumonitis (fHP). This study aims to explore survival between patients with IPF and fHP substratified by presence or absence of self-reported familial pulmonary fibrosis.</p><p><strong>Methods: </strong>Family history was acquired systematically, and patients were stratified by IPF or fHP according to specific guidelines.  Clinical data on pulmonary function and imaging were collected during the first follow-up evaluation of patients. All cases were reviewed in multidisciplinary meetings. Other ILD diagnosis was excluded.   RESULTS: A total of 198 participants were included: 88 with IPF and 110 with fHP. In the IPF group, 36 had familial forms (F-IPF), and in the fHP group, 30 had familial fHP (F-fHP). The median follow-up time was 37 (3 - 1200) months. The variables age (hazard ratio [HR]: 1.03; 95% CI: 1.01 - 1.06; p = 0.01), FVC% (HR: 0.96; 95% CI: 0.94 - 0.98; p < 0.01), SpO2% (HR: 0.86; 95% CI: 0.76 - 0.97; p < 0.02), and family history of pulmonary fibrosis (HR: 1.79; 95% CI: 1.09 - 2.93; p = 0.02) were associated with mortality and were controlled before performing the survival curves. The median survival for the FPF group was 46 months compared to 75 months for the non-familial group (p = 0.009).</p><p><strong>Conclusion: </strong>patients with familial presentations of IPF and fHP have significantly lower survival compared to patients with non-familial presentations of the same diseases. In clinical practice across many countries, genetic testing is not widely available, so family history should always be investigated.</p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"42 4","pages":"16938"},"PeriodicalIF":0.0000,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12815290/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36141/svdld.v42i4.16938","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Familial pulmonary fibrosis (FPF) is defined as the occurrence of any interstitial lung disease (ILD) in two or more first- or second-degree relatives. Although the most frequently reported phenotype is idiopathic pulmonary fibrosis (IPF), other forms of ILD have been identified, such as fibrotic hypersensitivity pneumonitis (fHP). This study aims to explore survival between patients with IPF and fHP substratified by presence or absence of self-reported familial pulmonary fibrosis.

Methods: Family history was acquired systematically, and patients were stratified by IPF or fHP according to specific guidelines.  Clinical data on pulmonary function and imaging were collected during the first follow-up evaluation of patients. All cases were reviewed in multidisciplinary meetings. Other ILD diagnosis was excluded.   RESULTS: A total of 198 participants were included: 88 with IPF and 110 with fHP. In the IPF group, 36 had familial forms (F-IPF), and in the fHP group, 30 had familial fHP (F-fHP). The median follow-up time was 37 (3 - 1200) months. The variables age (hazard ratio [HR]: 1.03; 95% CI: 1.01 - 1.06; p = 0.01), FVC% (HR: 0.96; 95% CI: 0.94 - 0.98; p < 0.01), SpO2% (HR: 0.86; 95% CI: 0.76 - 0.97; p < 0.02), and family history of pulmonary fibrosis (HR: 1.79; 95% CI: 1.09 - 2.93; p = 0.02) were associated with mortality and were controlled before performing the survival curves. The median survival for the FPF group was 46 months compared to 75 months for the non-familial group (p = 0.009).

Conclusion: patients with familial presentations of IPF and fHP have significantly lower survival compared to patients with non-familial presentations of the same diseases. In clinical practice across many countries, genetic testing is not widely available, so family history should always be investigated.

Abstract Image

家族性特发性肺纤维化和纤维化超敏性肺炎的生存率。
背景:家族性肺纤维化(FPF)被定义为两个或多个一级或二级亲属发生任何间质性肺疾病(ILD)。虽然最常报道的表型是特发性肺纤维化(IPF),但也发现了其他形式的ILD,如纤维化过敏性肺炎(fHP)。本研究旨在探讨IPF和fHP患者的生存率,这些患者是否存在自我报告的家族性肺纤维化。方法:系统地获取家族史,并根据特定的指南采用IPF或fHP对患者进行分层。在患者的第一次随访评估中收集肺功能和影像学的临床资料。所有病例都在多学科会议上进行了审查。排除其他ILD诊断。结果:共纳入198例受试者:IPF 88例,fHP 110例。在IPF组中,有36例患有家族性fHP (F-IPF),在fHP组中,有30例患有家族性fHP (F-fHP)。中位随访时间为37(3 ~ 1200)个月。年龄(风险比[HR]: 1.03; 95% CI: 1.01 ~ 1.06; p = 0.01)、FVC% (HR: 0.96; 95% CI: 0.94 ~ 0.98; p < 0.01)、SpO2% (HR: 0.86; 95% CI: 0.76 ~ 0.97; p < 0.02)和肺纤维化家族史(HR: 1.79; 95% CI: 1.09 ~ 2.93; p = 0.02)与死亡率相关,在绘制生存曲线前进行控制。FPF组的中位生存期为46个月,而非家族性组为75个月(p = 0.009)。结论:家族性IPF和fHP患者的生存率明显低于非家族性相同疾病的患者。在许多国家的临床实践中,基因检测并不普遍,因此应该始终调查家族史。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书